Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how a skin disease drug works in everyday life

NCT ID NCT05921994

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study follows 435 adults with moderate to severe hidradenitis suppurativa (a painful skin condition) who are taking secukinumab. Researchers want to see how doctors adjust the dose over two years and how well the treatment controls symptoms like abscesses and pain. The goal is to understand real-world use, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

436 people

The number who actually took part.

Started

Aug 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment: 1. Patients who provide written informed consent to participate in the study 2. Male and female patients with ≥18 years of age 3. Diagnosis of clinically unequivocal moderate to severe HS 4. Patients for whom a therapy with secukinumab is medically indicated 5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study 6. Treatment with secukinumab according to the latest version of SmPC 7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit Exclusion Criteria: Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients: 1. Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC 2. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation 3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab 4. Previous exposure to IL-17 inhibitors 5. For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79068, Germany

  • Novartis Investigative Site

    Rheinstetten, Baden-Wurttemberg, 76287, Germany

  • Novartis Investigative Site

    Haßfurt, Bavaria, 97437, Germany

  • Novartis Investigative Site

    Kulmbach, Bavaria, 95326, Germany

  • Novartis Investigative Site

    Lauf an der Pegnitz, Bavaria, 91207, Germany

  • Novartis Investigative Site

    Nuremberg, Bavaria, 90402, Germany

  • Novartis Investigative Site

    Panketal, Brandenburg, 16341, Germany

  • Novartis Investigative Site

    Hamburg, Free and Hanseatic City of Hamburg, 22549, Germany

  • Novartis Investigative Site

    Lingen, Lower Saxony, 49809, Germany

  • Novartis Investigative Site

    Bergen auf Rügen, Mecklenburg-Vorpommern, 18528, Germany

  • Novartis Investigative Site

    Kröpelin, Mecklenburg-Vorpommern, 18236, Germany

  • Novartis Investigative Site

    Krefeld, North Rhine-Westphalia, 47798, Germany

  • Novartis Investigative Site

    Mainz, Rhineland-Palatinate, 55128, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04207, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04289, Germany

  • Novartis Investigative Site

    Wittenberg, Saxony-Anhalt, 06886, Germany

  • Novartis Investigative Site

    Aachen, 52064, Germany

  • Novartis Investigative Site

    Ahaus, 48683, Germany

  • Novartis Investigative Site

    Annaberg-Buchholz, 09456, Germany

  • Novartis Investigative Site

    Bad Steben, 95138, Germany

  • Novartis Investigative Site

    Baden-Baden, 76530, Germany

  • Novartis Investigative Site

    Berlin, 12159, Germany

  • Novartis Investigative Site

    Berlin, 13595, Germany

  • Novartis Investigative Site

    Bielefeld, 33647, Germany

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    Brandenburg, 14776, Germany

  • Novartis Investigative Site

    Bremen, 28359, Germany

  • Novartis Investigative Site

    Buxtehude, 21614, Germany

  • Novartis Investigative Site

    Bückeburg, 31675, Germany

  • Novartis Investigative Site

    Chemnitz, 09113, Germany

  • Novartis Investigative Site

    Chemnitz, 09117, Germany

  • Novartis Investigative Site

    Cologne, 51065, Germany

  • Novartis Investigative Site

    Delitzsch, 04509, Germany

  • Novartis Investigative Site

    Dessau, 06847, Germany

  • Novartis Investigative Site

    Dorsten, 46282, Germany

  • Novartis Investigative Site

    Dortmund, 44137, Germany

  • Novartis Investigative Site

    Dresden, 01309, Germany

  • Novartis Investigative Site

    Düren, 52349, Germany

  • Novartis Investigative Site

    Emsdetten, 48282, Germany

  • Novartis Investigative Site

    Erlangen, 91054, Germany

  • Novartis Investigative Site

    Falkenberg, 04895, Germany

  • Novartis Investigative Site

    Falkensee, 14612, Germany

  • Novartis Investigative Site

    Freising, 85354, Germany

  • Novartis Investigative Site

    Geilenkirchen, 52511, Germany

  • Novartis Investigative Site

    Gera, 07548, Germany

  • Novartis Investigative Site

    Gernsbach, 76593, Germany

  • Novartis Investigative Site

    Gladbeck, 45964, Germany

  • Novartis Investigative Site

    Großenhain, 01558, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Hamburg, 22143, Germany

  • Novartis Investigative Site

    Hanover, 30159, Germany

  • Novartis Investigative Site

    Haslach im Kinzigtal, 77716, Germany

  • Novartis Investigative Site

    Hofgeismar, 34369, Germany

  • Novartis Investigative Site

    Jena, 07743, Germany

  • Novartis Investigative Site

    Jülich, 52428, Germany

  • Novartis Investigative Site

    Karlsruhe, 76133, Germany

  • Novartis Investigative Site

    Kempen, 47906, Germany

  • Novartis Investigative Site

    Lübeck, 23538, Germany

  • Novartis Investigative Site

    Magdeburg, 39104, Germany

  • Novartis Investigative Site

    Magdeburg, 39120, Germany

  • Novartis Investigative Site

    Mainz, 55116, Germany

  • Novartis Investigative Site

    Marburg, 35043, Germany

  • Novartis Investigative Site

    Minden, 32429, Germany

  • Novartis Investigative Site

    Mönchengladbach, 41063, Germany

  • Novartis Investigative Site

    Neu Wulmstorf, 21629, Germany

  • Novartis Investigative Site

    Nuremberg, 90419, Germany

  • Novartis Investigative Site

    Oberasbach, 90522, Germany

  • Novartis Investigative Site

    Oelde, 59302, Germany

  • Novartis Investigative Site

    Peitz, 03185, Germany

  • Novartis Investigative Site

    Potsdam, 14469, Germany

  • Novartis Investigative Site

    Remscheid, 42897, Germany

  • Novartis Investigative Site

    Selters, 56242, Germany

  • Novartis Investigative Site

    Simmern, 55469, Germany

  • Novartis Investigative Site

    Soest, 59494, Germany

  • Novartis Investigative Site

    Stolberg, 52222, Germany

  • Novartis Investigative Site

    Unna, 59423, Germany

  • Novartis Investigative Site

    Wittlich, 54316, Germany

  • Novartis Investigative Site

    Wuppertal, 42103, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.